登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：600257 公司简称：大湖股份 第一节 重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读半年度报告全文。 1.2本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.3公司全体董事出席董事会会议。 1.4本半年度报告未经审计。 1.5董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 第二节 公司基本情况 2.1公司简介 ■ 2.2主要财务数据 单位：元 币种：人民币 ■ 2.3前10名股东持股情况表 单位: 股 ■ 2.4截至报告期末的优先股股东总数、前10名优先股股东情况表 □适用 √不适用 2.5控股股东或实际控制人变更情况 □适用 √不适用 2.6在半年度报告批准报出日存续的债券情况 □适用 √不适用 第三节 重要事项 公司应当根据重要性原则，说明报告期内公司经营情况的重大变化，以及报告期内发生的对公司经营情 况有 ...

大湖水殖股份有限公司（以下简称"公司"）第九届监事会第十 三次会议于 2025 年 7 月 14 日发出了召开监事会会议的通知。会议于 监事 3 名，实到监事 3 名，符合《公司法》和《公司章程》的规定。 会议由监事会主席陈颢先生主持，会议审议通过了如下议案： 一、审议通过了《关于公司 2025 年半年度报告及摘要的议案》 公司根据中国证监会《公开发行证券的公司信息披露内容与格式 准则第 2 号--年度报告的内容与格式》《上海证券交易所股票上市规 则》及其他有关法律法规的规定，编制了《公司 2025 年半年度报告》 及《公司 2025 年半年度报告摘要》 表决结果：同意 3 票，反对 0 票，弃权 0 票，该议案获得全体监 事全票表决通过。 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn） 的《大湖水殖股份有限公司 2025 年半年度报告》及《大湖水殖股份 有限公司 2025 年半年度报告摘要》 证券代码：600257 证券简称：大湖股份 公告编号：2025-028 大湖水殖股份有限公司 第九届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性 ...

Group 1 - Leshan Electric achieved operating revenue of 1.623 billion yuan, a year-on-year increase of 1.94%, and a net profit of 7.9031 million yuan, a year-on-year decrease of 14.55% [1] - Zhimingda reported operating revenue of 295 million yuan, a year-on-year increase of 84.83%, and a net profit of 38.3 million yuan, a year-on-year increase of 2147.93% [2] - Dahu Co. reported operating revenue of 426 million yuan, a year-on-year decrease of 14.40%, and a net loss of 2.5716 million yuan, an improvement from a loss of 13.7824 million yuan in the same period last year [3] - Yubang Electric expects a net profit of 21.2 million to 25 million yuan, a year-on-year decrease of 35.47% to 45.28% [4] - Zhejiang Securities achieved operating revenue of 6.512 billion yuan, a year-on-year decrease of 18.60%, and a net profit of 1.149 billion yuan, a year-on-year increase of 46.54% [5] - Huashu Media reported operating revenue of 4.435 billion yuan, a year-on-year increase of 2.07%, and a net profit of 254 million yuan, a year-on-year increase of 4.63% [7] Group 2 - Sinopec reported oil and gas equivalent production of 262.81 million barrels, a year-on-year increase of 2%, and crude oil processing volume of 119.97 million tons, a year-on-year decrease of 5.3% [8] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS8179, aimed at reducing brain edema after stroke [8] - Hengrui Medicine's subsidiary also received approval for clinical trials of HRS-1893, intended for treating heart failure with preserved ejection fraction [8] - Wanfu Co. announced a plan to reduce its stake by up to 2% through block trading [10] - Biological Co. received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inaccuracies in financial reporting [11] - Zhujiang Co. reported a signed construction area of 47.1432 million square meters across 396 projects [13] Group 3 - Watson Bio received a patent for a peptide delivery system for RNA drugs [15] - Sanwei Chemical signed 31 new contracts worth 335 million yuan in the second quarter [17] - Shenzhou Cell's SCT640C injection received approval for clinical trials for rheumatoid arthritis [18] - Xinjiang Jiaojian reported new contracts worth 1.434 billion yuan in the second quarter [19] - Lais Information plans to use 550 million yuan of idle funds for cash management [21] - Zhongqi New Materials signed a mining rights transfer contract, increasing production capacity [22] Group 4 - Hengtong Optic-Electric won multiple marine energy projects worth 1.509 billion yuan [24] - China State Construction signed new contracts totaling 2.501 trillion yuan in the first half of the year [26] - David Medical's ventilator product registration application has been accepted [28] - Tianhai Defense's subsidiary signed a construction contract worth 16.224 million yuan [29] - Nantian Information plans to sign a procurement framework contract worth 58.27 million yuan with its controlling shareholder [31] - Baida Group announced a plan to reduce its stake by up to 3% [32] Group 5 - Jinli Permanent Magnet plans to issue $117.5 million in convertible bonds [34] - Haizheng Pharmaceutical's fumarate bedaquiline raw material drug application has been approved [36] - Huatai passed the advanced intelligent factory re-evaluation in Anhui Province [37] - Everbright Bank's shareholder increased its stake from 7.08% to 8% [40] - Supor reported total operating revenue of 11.478 billion yuan, a year-on-year increase of 4.68%, and a net profit of 940 million yuan, a year-on-year decrease of 0.07% [41] - Qianjin Pharmaceutical's subsidiaries received registration certificates for two drugs [42]

证券代码：600257 证券简称：大湖股份 公告编号：2025-028 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn） 的《大湖水殖股份有限公司 2025 年半年度报告》及《大湖水殖股份 有限公司 2025 年半年度报告摘要》。 特此公告。 大湖水殖股份有限公司 监 事 会 第九届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 大湖水殖股份有限公司（以下简称"公司"）第九届监事会第十 三次会议于 2025 年 7 月 14 日发出了召开监事会会议的通知。会议于 2025 年 7 月 24 日在本公司会议室以现场表决的方式召开召开，应到 监事 3 名，实到监事 3 名，符合《公司法》和《公司章程》的规定。 会议由监事会主席陈颢先生主持，会议审议通过了如下议案： 一、审议通过了《关于公司 2025 年半年度报告及摘要的议案》 公司根据中国证监会《公开发行证券的公司信息披露内容与格式 准则第 2 号--年度报告的内容与格式》《上海证券交易所股票上市规 则》及其他有关法律法 ...

证券代码：600257 证券简称：大湖股份 公告编号：2025-027 公司根据中国证监会《公开发行证券的公司信息披露内容与格式 准则第 2 号--年度报告的内容与格式》《公开发行证券的公司信息披 露内容与格式准则第 3 号--半年度报告的内容与格式》《上海证券交 易所股票上市规则》及其他有关法律法规的规定，编制了《公司 2025 年半年度报告》及《公司 2025 年半年度报告摘要》。 表决结果：同意 5 票，反对 0 票，弃权 0 票，该议案获得全体董 事全票表决通过。 该议案已经公司董事会审计委员会 2025 年第四次会议审议通过， 审计委员会对公司 2025 年半年度报告进行了事前审阅，认为公司 2025 年半年度报告符合公司实际，基本反映了公司的生产经营状况， 半年度报告的内容真实、准确、完整，全体委员一致同意提交董事会 审议。 具体内容详见上海证券交易所网站（http://www.sse.com.cn） 披露的《大湖水殖股份有限公司 2025 年半年度报告》及《大湖水殖 股份有限公司 2025 年半年度报告摘要》。 特此公告。 大湖水殖股份有限公司 大湖水殖股份有限公司 第九届董事会第十七次会议决议 ...

Definitions [Definitions of Common Terms](index=4&type=section&id=%E5%B8%B8%E7%94%A8%E8%AF%8D%E8%AF%AD%E9%87%8A%E4%B9%89) This section defines key terms such as the Company, controlling shareholder, and major business entities to ensure precise communication throughout the report - The report clarifies that **'the Company' refers to Dahu Aquaculture Co., Ltd.**, **'Controlling Shareholder' refers to Tibet Hongshan Technology Development Co., Ltd.**, and specifies key business entities like **'Two Lakes and Two Reservoirs'**, **Dongfang Huakang**, and **Deshan Wine Industry**[16](index=16&type=chunk) Company Profile and Key Financial Indicators [Company Information](index=4&type=section&id=%E5%85%AC%E5%8F%B8%E4%BF%A1%E6%81%AF) This section provides the Company's fundamental corporate details, including contact information, addresses, disclosure channels, and stock overview Company Basic Information | Item | Information | | :--- | :--- | | **Company Name** | Dahu Aquaculture Co., Ltd. (Dahu Shares) | | **Stock Code** | 600257 (Shanghai Stock Exchange) | | **Legal Representative** | Luo Dingkun | | **Information Disclosure Newspapers** | China Securities Journal, Shanghai Securities News, Securities Times | | **Information Disclosure Website** | www.sse.com.cn | [Key Accounting Data and Financial Indicators](index=5&type=section&id=%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) In H1 2025, the Company's operating revenue decreased by **14.40%**, while total profit surged by **136.28%**, and net loss attributable to shareholders narrowed by **81.34%**, driven by improved operating cash flow from increased sales collections and reduced procurement 2025 Half-Year Key Accounting Data (Unit: RMB) | Key Accounting Data | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 425,544,826.66 | 497,127,058.26 | -14.40 | | Total Profit | 22,861,467.67 | 9,675,784.88 | 136.28 | | Net Profit Attributable to Shareholders of Listed Company | -2,571,624.48 | -13,782,393.98 | 81.34 | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | -4,539,093.45 | -16,760,401.07 | 72.92 | | Net Cash Flow from Operating Activities | 84,213,927.49 | -104,152,373.58 | N/A | | Total Assets (Period-End) | 1,858,831,277.71 | 1,860,201,296.68 | -0.07 | - Net cash flow from operating activities significantly improved year-on-year, primarily due to shortened accounts receivable credit terms, leading to a **27.25 million RMB** increase in sales collections, and a **129.82 million RMB** reduction in cash paid for goods and services[23](index=23&type=chunk) [Non-Recurring Gains and Losses Items and Amounts](index=6&type=section&id=%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) During the reporting period, the Company's total non-recurring gains and losses amounted to **1.97 million RMB**, primarily from government subsidies, fair value changes in financial assets, and interest income from funds occupied by non-financial enterprises 2025 Half-Year Non-Recurring Gains and Losses Items (Unit: RMB) | Non-Recurring Gains and Losses Item | Amount | | :--- | :--- | | Government Subsidies | 2,320,486.19 | | Gains/Losses from Fair Value Changes and Disposal of Financial Assets and Liabilities | 369,520.39 | | Interest Income from Funds Occupied by Non-Financial Enterprises | 402,222.23 | | Net Other Non-Operating Income and Expenses | 189,244.10 | | Debt Restructuring Gains/Losses | -226,412.75 | | **Total** | **1,967,468.97** | Management Discussion and Analysis [Industry and Principal Business Overview](index=7&type=section&id=%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E5%8F%8A%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5) The Company strategically focuses on the big health industry, operating two main segments: health product production and sales (aquaculture, liquor, health supplements) and health medical services (rehabilitation, nursing), with aquaculture benefiting from policy support, liquor facing consumption upgrades, and rehabilitation medical services driven by an aging population - The Company has established **'Health Products + Health Medical Services'** as its two core business segments, aligning with China's 'Healthy China' strategy and market demand[27](index=27&type=chunk) - Aquaculture Industry: National policies continuously promote ecological fisheries and the pre-prepared food industry, creating opportunities for the Company's aquaculture and processing businesses, with China's pre-prepared food market size projected to exceed **1.07 trillion RMB** by 2026[38](index=38&type=chunk)[41](index=41&type=chunk)[48](index=48&type=chunk) - Liquor Industry: The industry is becoming more standardized, with consumption trends shifting towards branding and quality, posing competitive pressure on regional brands from national renowned liquors[49](index=49&type=chunk)[51](index=51&type=chunk) - Rehabilitation and Nursing Medical Industry: Benefiting from an aging population and national policy support, rehabilitation demand continues to grow, with significant market potential, as China's rehabilitation medical market size is expected to exceed **220 billion RMB** by 2025[51](index=51&type=chunk)[55](index=55&type=chunk) [Principal Business Operations](index=7&type=section&id=%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5) The Company's principal businesses are categorized into four types: live aquatic products using large-surface green farming, chilled and frozen aquatic products via order-based production, liquor with traditional brewing techniques, and rehabilitation nursing medical services primarily in the Yangtze River Delta region - **Live Aquatic Products**: The Company possesses approximately **168,000 mu** of freshwater aquaculture area, utilizing a 'catch-as-you-sell' model, with sales concentrated in Central-South, Southwest, East, and North China regions[28](index=28&type=chunk)[29](index=29&type=chunk) - **Chilled and Frozen Aquatic Products**: Employing an 'order-based production' model, the Company collaborates closely with core channels like Walmart Sam's Club and Tianhong, with a marketing network covering multiple regions nationwide[30](index=30&type=chunk)[31](index=31&type=chunk) - **Liquor**: The Company owns the 'Deshan' Chinese time-honored brand, with products covering sauce, strong, and mixed aroma types, primarily adopting a dealer-based sales model[32](index=32&type=chunk)[34](index=34&type=chunk) - **Rehabilitation and Nursing Medical Services**: Through its subsidiary Dongfang Huakang, the Company operates multiple rehabilitation and nursing institutions in Shanghai, Changzhou, Wuxi, and Hangzhou, ranking among the larger privately-run health and elderly care medical institutions in the Yangtze River Delta region[35](index=35&type=chunk) [Discussion and Analysis of Operations](index=15&type=section&id=%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E7%9A%84%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) In H1 2025, the Company achieved **426 million RMB** in operating revenue and a net loss attributable to shareholders of **-2.57 million RMB**, narrowing the loss by **11.28 million RMB** year-on-year, primarily driven by strong growth in frozen aquatic products, while liquor and medical businesses experienced revenue declines - Frozen aquatic products business performed strongly, with H1 revenue growing by **14.99%** year-on-year, new products like Thai Curry Shrimp and Huadiao Drunken Crab contributing **30.79 million RMB** in revenue, and crayfish series products generating **142 million RMB**, up **19.90%** year-on-year[56](index=56&type=chunk) - Liquor product sales declined due to consumption downgrades and intensified regional market competition, resulting in a **17.00%** year-on-year decrease in operating revenue[56](index=56&type=chunk) - Overall medical business revenue decreased by **8.36%** year-on-year, with hospitals in Changzhou and Wuxi experiencing revenue declines, while Shanghai Jincheng Nursing Home maintained a bed utilization rate of approximately **98%**, with revenue growing by **11.52%** year-on-year[57](index=57&type=chunk) [Core Competitiveness Analysis](index=16&type=section&id=%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The Company's core competitiveness stems from three key advantages: long-term usage rights for **'Two Lakes and Two Reservoirs'**, strong brand recognition with **'Dahu'** and **'Deshan'** trademarks, and advanced ecological aquaculture, water treatment, and traditional liquor brewing technologies - **Resource Advantage**: The Company holds long-term usage rights for the operated **'Two Lakes and Two Reservoirs'**, providing an excellent foundation for business development with superior water quality[60](index=60&type=chunk) - **Brand and Product Advantage**: **'Dahu'** and **'Deshan'** are both China Well-known Trademarks; **'Dahu'** brand aquatic products are organically certified and have won multiple brand awards, while **'Deshan'** liquor's ancient brewing technique is listed as a provincial intangible cultural heritage[61](index=61&type=chunk)[64](index=64&type=chunk) - **Technology and Environmental Advantage**: The Company collaborates with research institutions to innovate ecological aquaculture models and possesses core water environment governance technologies; Deshan Wine Industry is located in an excellent ecological brewing environment with a long history of winemaking[62](index=62&type=chunk)[63](index=63&type=chunk) [Analysis of Key Operating Performance](index=18&type=section&id=%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E4%B8%BB%E8%A6%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5) This section analyzes the Company's operating status through financial statement item changes, noting decreased revenue and costs, reduced selling, general, and administrative expenses, leading to narrowed losses, increased cash, decreased prepayments, and partial repayment of long-term borrowings Analysis of Major Income Statement Items Changes (Unit: RMB) | Item | Current Period Amount | Prior Period Amount | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 425,544,826.66 | 497,127,058.26 | -14.40 | | Operating Cost | 319,159,915.19 | 378,040,605.09 | -15.58 | | Selling Expenses | 9,087,882.15 | 13,705,794.46 | -33.69 | | Administrative Expenses | 54,182,081.10 | 63,426,006.11 | -14.57 | | Financial Expenses | 16,039,098.41 | 18,711,715.95 | -14.28 | Analysis of Major Balance Sheet Items Changes | Item Name | Change (%) | Explanation | | :--- | :--- | :--- | | Cash and Cash Equivalents | 24.53 | Primarily due to increased cash flow from operating activities | | Financial Assets Held for Trading | 45.90 | Primarily due to the use of idle funds to purchase structured deposits | | Prepayments | -51.04 | Primarily due to the completion of delivery and sale of goods corresponding to crayfish procurement prepayments made earlier | | Long-term Borrowings | -32.12 | Primarily due to repayment of long-term bank loans | - The Company and Dongfang Huakang jointly invested to establish Shanghai Kuaizhi Medical Technology Co., Ltd. on March 4, 2025, with a registered capital of **5 million RMB**, and the Company holding an **80%** stake[70](index=70&type=chunk) [Potential Risks](index=22&type=section&id=%E5%8F%AF%E8%83%BD%E9%9D%A2%E5%AF%B9%E7%9A%84%E9%A3%8E%E9%99%A9) The Company details key operating risks in this report, including product market competition, food safety, operating cost fluctuations, management risks from business expansion, and operational risks within the medical industry - **Market Competition Risk**: Dahu live fish face quantity advantage competition from pond-farmed fish; liquor products, as regional brands, face market pressure from national renowned liquors[73](index=73&type=chunk) - **Food Safety Risk**: Any hygiene inspection or food safety issues could adversely impact the Company's reputation, sales, and performance[74](index=74&type=chunk) - **Cost Fluctuation Risk**: Rising costs for labor, fish fry procurement, and factors like natural disasters or fish diseases could lead to significant fluctuations in operating costs[75](index=75&type=chunk)[76](index=76&type=chunk) - **Management and Medical Operation Risk**: Expanding business scale and cross-industry mergers and acquisitions (medical services) introduce risks related to management integration, medical safety, and quality[76](index=76&type=chunk)[77](index=77&type=chunk) Corporate Governance, Environment, and Society [Corporate Governance Status](index=24&type=section&id=%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E6%83%85%E5%86%B5) During the reporting period, there were no changes in the Company's directors, supervisors, or senior management, and the half-year profit distribution plan proposed no distribution or capital reserve capitalization, with no equity incentive or employee stock ownership plans - There were no changes in the Company's directors, supervisors, or senior management during the reporting period[80](index=80&type=chunk) - The proposed half-year profit distribution plan is to not distribute profits or convert capital reserves into share capital[80](index=80&type=chunk) [Environmental Information](index=24&type=section&id=%E7%8E%AF%E5%A2%83%E4%BF%A1%E6%81%AF%E6%83%85%E5%86%B5) The Company adheres to an ecological aquaculture philosophy of 'natural rearing and growth,' improving and restoring aquatic ecosystems through filter-feeding fish farming and bioremediation technologies to promote green and sustainable development - The Company adopts a natural stocking ecological aquaculture model, where fish like bighead carp and silver carp are not fed, consuming plankton to help purify water quality, achieving low energy consumption, low pollution, and low emissions[81](index=81&type=chunk) - The Company utilizes technologies such as biological metabolic restoration and lake ecosystem food web regulation, optimizing aquatic organism stocking structures and restoring aquatic plant communities to biologically manage water bodies and improve the ecological environment[82](index=82&type=chunk) Significant Matters [Fulfillment of Commitments](index=26&type=section&id=%E6%89%BF%E8%AF%BA%E4%BA%8B%E9%A1%B9%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) The performance commitment related to the acquisition of Dongfang Huakang remains within its fulfillment period, with the original commitment party pledging Dongfang Huakang to achieve cumulative net profits of **245 million RMB** over five years from 2020 to 2025 (excluding 2022) - Dongfang Huakang's performance commitment party pledged cumulative net profits of **20 million RMB** for 2020, **60 million RMB** for 2021, **105 million RMB** for 2023, **165 million RMB** for 2024, and **245 million RMB** for 2025[86](index=86&type=chunk)[87](index=87&type=chunk) [Significant Related Party Transactions](index=30&type=section&id=%E9%87%8D%E5%A4%A7%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) The Company anticipates total annual related party transactions for 2025 not exceeding **5.71 million RMB**, with **1.46 million RMB** incurred as of June 30, 2025, primarily involving product procurement, sales, property and security services, and asset leasing - The total estimated amount for routine related party transactions in 2025 will not exceed **5.71 million RMB**[91](index=91&type=chunk) - As of the end of the reporting period, related party transactions amounted to **1.46 million RMB**, primarily including procurement of products and services from related parties, as well as asset leasing[92](index=92&type=chunk)[93](index=93&type=chunk) [Significant Contracts and Their Fulfillment](index=32&type=section&id=%E9%87%8D%E5%A4%A7%E5%90%88%E5%90%8C%E5%8F%8A%E5%85%B6%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) As of the end of the reporting period, the Company's total guarantee balance for subsidiaries was **364 million RMB**, representing **45.63%** of its net assets, including **44 million RMB** for entities with a debt-to-asset ratio exceeding **70%** Company Guarantee Total Amount (Unit: RMB) | Item | Amount (RMB) | | :--- | :--- | | Total Guarantee Balance for Subsidiaries at Period-End (B) | 363,597,144.10 | | Ratio of Total Guarantees to Company's Net Assets (%) | 45.63 | | Debt Guarantee Amount Provided for Guaranteed Entities with Debt-to-Asset Ratio Exceeding 70% (D) | 44,000,000.00 | Share Changes and Shareholder Information [Share Capital Changes](index=35&type=section&id=%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, there were no changes in the Company's total share capital or shareholding structure - During the reporting period, there were no changes in the Company's total share capital or shareholding structure[103](index=103&type=chunk) [Shareholder Information](index=35&type=section&id=%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) As of the end of the reporting period, the Company had **46,166** common shareholders, with controlling shareholder Tibet Hongshan Technology Development Co., Ltd. holding **25.9951%** and increasing its stake by **20,467,001** shares during the period - As of the end of the reporting period, the Company had a total of **46,166** common shareholders[104](index=104&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shares Held at Period-End | Percentage (%) | | :--- | :--- | :--- | | Tibet Hongshan Technology Development Co., Ltd. | 125,098,212 | 25.9951 | | Fan Yuanlong | 13,953,762 | 2.90 | | Yu Yiping | 6,384,700 | 1.33 | | Lin Weiping | 3,479,700 | 0.72 | | Liang Baihong | 2,713,400 | 0.56 | Bond-Related Information [Corporate Bonds and Non-Financial Enterprise Debt Financing Instruments](index=38&type=section&id=%E5%85%AC%E5%8F%B8%E5%80%BA%E5%88%B8%E5%92%8C%E9%9D%9E%E9%87%91%E8%9E%8D%E4%BC%81%E4%B8%9A%E5%80%BA%E5%8A%A1%E8%9E%8D%E8%B5%84%E5%B7%A5%E5%85%B7) During the reporting period, the Company had no outstanding corporate bonds, enterprise bonds, or non-financial enterprise debt financing instruments - The Company had no corporate bonds or non-financial enterprise debt financing instruments during this reporting period[110](index=110&type=chunk) Financial Report [Financial Statements](index=39&type=section&id=%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section includes the Company's unaudited 2025 half-year consolidated and parent company financial statements, comprising the balance sheet, income statement, cash flow statement, and statement of changes in equity - This half-year report is unaudited[5](index=5&type=chunk) - Consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in equity are provided[112](index=112&type=chunk)[115](index=115&type=chunk)[118](index=118&type=chunk)[121](index=121&type=chunk)[124](index=124&type=chunk)[127](index=127&type=chunk)[131](index=131&type=chunk)[138](index=138&type=chunk) [Significant Accounting Policies and Estimates](index=63&type=section&id=%E9%87%8D%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%94%BF%E7%AD%96%E5%8F%8A%E4%BC%9A%E8%AE%A1%E4%BC%B0%E8%AE%A1) This section details the Company's fundamental accounting principles, including accounting standards, period, and functional currency, along with specific accounting policies and estimates for financial instruments, inventories, long-term equity investments, revenue recognition, and government grants - Financial statements are prepared on a going concern basis, with the accounting year from January 1 to December 31 of the Gregorian calendar, and the functional currency being RMB[146](index=146&type=chunk)[150](index=150&type=chunk)[152](index=152&type=chunk) - Revenue recognition policy: Revenue is recognized when the customer obtains control of the related goods; sales of aquatic products and liquor are recognized at the point of delivery; medical services are recognized over the period of performance as the customer simultaneously obtains and consumes the economic benefits[238](index=238&type=chunk)[241](index=241&type=chunk) - Impairment of financial assets: Impairment provisions are recognized based on expected credit losses; for receivables without significant financing components, the simplified approach is used to measure expected credit losses over the entire lifetime; other financial assets are measured using the 'three-stage' model[180](index=180&type=chunk)[187](index=187&type=chunk) [Notes to Consolidated Financial Statement Items](index=96&type=section&id=%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E9%A1%B9%E7%9B%AE%E6%B3%A8%E9%87%8A) This section provides detailed notes and explanations for major items in the consolidated financial statements, including the composition, changes, and related accounting treatments for cash and cash equivalents, accounts receivable, inventories, fixed assets, intangible assets, goodwill, short-term borrowings, accounts payable, and deferred tax assets/liabilities - Period-end cash and cash equivalents totaled **233 million RMB**, including **44,700 RMB** in restricted funds[268](index=268&type=chunk)[424](index=424&type=chunk) - Period-end accounts receivable had a book balance of **149 million RMB**, with bad debt provisions of **27.26 million RMB**, resulting in a carrying value of **121 million RMB**; the top five debtors accounted for **74.37%** of the total[276](index=276&type=chunk)[284](index=284&type=chunk) - Period-end inventory had a carrying value of **446 million RMB**, primarily comprising consumable biological assets (**284 million RMB**) and work-in-progress (**104 million RMB**)[301](index=301&type=chunk) - Period-end goodwill had a carrying value of **136 million RMB**, primarily arising from the acquisition of Dongfang Huakang Medical Management Co., Ltd[334](index=334&type=chunk)[337](index=337&type=chunk)

Group 1 - The high-pressure oxygen chamber concept increased by 1.55%, ranking second among concept sectors, with three stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading gainers in the high-pressure oxygen chamber sector were International Medicine and Yinkang Life, which rose by 0.93% and 0.20% respectively [1] - The sector saw a net inflow of 0.50 billion yuan from main funds, with Tiebian Heavy Industry receiving the highest net inflow of 1.03 billion yuan [2][3] Group 2 - The main fund inflow ratios for Tiebian Heavy Industry, International Medicine, and Jinling Pharmaceutical were 29.36%, 10.10%, and 5.54% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed varied results, with Tiebian Heavy Industry leading in both price increase and fund inflow [3][4] - Stocks such as Weiao and Innovation Medical experienced significant declines, with net outflows of -3214.35 million yuan and -4427.60 million yuan respectively [4]

Group 1 - The high-pressure oxygen chamber concept increased by 2.63%, ranking 10th among concept sectors, with five stocks rising, including a 20% limit-up for Tiedao Heavy Industry [1] - Notable gainers in the high-pressure oxygen chamber sector include Innovation Medical and Samsung Medical, which rose by 3.29% and 0.96% respectively [1] - The sector experienced a net inflow of 170 million yuan from main funds, with Tiedao Heavy Industry receiving the highest net inflow of 120 million yuan [2] Group 2 - The top stocks by net inflow ratio in the high-pressure oxygen chamber sector are Tiedao Heavy Industry at 39.19%, International Medical at 4.88%, and Samsung Medical at 4.16% [3] - The trading volume and turnover rates for key stocks in the sector indicate significant investor interest, with Tiedao Heavy Industry showing a turnover rate of 0.97% [3] - Decliners in the sector included Dahu Co., which fell by 0.55%, and Aoyang Health, which decreased by 0.50% [4]

Group 1 - The high-pressure oxygen chamber concept increased by 3.78%, ranking 8th among concept sectors, with 8 stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading stocks in the high-pressure oxygen chamber sector included Weiao Co., International Medicine, and Dahu Co., which rose by 3.80%, 3.24%, and 2.44% respectively [1] - The high-pressure oxygen chamber sector saw a net inflow of 152 million yuan from main funds, with 6 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow [2] Group 2 - The top net inflow stock was Tiebian Heavy Industry, with a net inflow of 60.89 million yuan, followed by International Medicine, Samsung Medical, and Aoyang Health with net inflows of 57.53 million yuan, 42.20 million yuan, and 22.89 million yuan respectively [2] - In terms of net inflow ratios, Aoyang Health, Tiebian Heavy Industry, and International Medicine had the highest ratios at 15.77%, 14.47%, and 11.68% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed significant activity, with Tiebian Heavy Industry achieving a daily increase of 19.90% and a turnover rate of 1.60% [3]

证券代码：600257 证券简称：大湖股份 公告编号：2025-026 公司于 2024 年 12 月 26 日在上海证券交易所网站披露了《公司 关于控股股东拟以专项贷款和自有资金增持公司股份计划的公告》 （公告编号：2024-033），控股股东西藏泓杉拟计划自该公告披露之 日起 12 个月，通过上海证券交易所交易系统以集中竞价方式增持公 司股份，累计增持金额不低于人民币 7,500 万元（含），不超过人民 币 1.5 亿元（含）。 公司于 2025 年 1 月 22 日在上海证券交易所网站披露了《关于控 股股东增持股份触及 1%的提示性公告》（公告编号：2025-007）， 西藏泓杉从 1 月 20 日至 1 月 21 日通过上海证券交易所系统以集中竞 大湖水殖股份有限公司 关于控股股东增持进展暨权益变动触及 1%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： ●本次权益变动属于大湖水殖股份有限公司（以下简称"公司"） 的控股股东西藏泓杉科技发展有限公司（以下简称"西藏泓杉"）增 持公司 ...